In rheumatoid arthritis treatment a shift towards the earlier use of DMARDs has threatened the dominance of the NSAID class of drugs. This has opened up considerable opportunity for drugs such as Remi
Would you do a clinical study in Spain? The immediate reaction of the majority of the international clinical research community is “maybe but only at the later stages (Phase III-b, Phase IV)”. Spain i
Due to the high incidence of migraine and its effect on quality of life the highly competitive triptan market exceeds of $2 billion in global sales. Triptans aborting a migraine attack once it has sta
Retinoids play a key role in differentiation, proliferation and apoptosis. As a result over 30 analogs of retinoic acid are now either in development or on the market. Retinoids in current use are eff
The proposed merger between Pfizer and Pharmacia will create a company with total ethical sales twice those of its nearest competitor. Declining R&D productivity, and a flood of patent expirations hav
The process of finding, screening, and recruiting clinical trial patients at multiple research sites is a challenge for even the largest pharmaceutical sponsors and clinical research organizations.
Dr Faiz Kermani
The growing number of ePrescribing, health information and other technological initiatives mean that IT is becoming an ever more important and integral part of the healthcare system, for doctors and p
Ever since it first came to market in 1993, the anticonvulsant drug Neurontin has consistently been one of Pfizer's top earners, generating considerable sales and driving strong growth for the New Yor
The pharmaceutical industry’s expectations for increasing revenue rely to a large extent on ensuring that their heavy R&D investment translates into new drugs. In 2000, the global pharmaceutical indu
High-dose therapy for multiple myeloma is effective in increasing median survival, but is severely toxic, limiting its use. In addition, all patients eventually relapse and suffer disease progression.
The pharmaceutical industry, much of which dreams of having the marketing agility of a primitive vertebrate, has found a sales-promotion tool that sometimes works in the United States and New Zealand.
It is now well established that cellular suicide (apoptosis or programmed cell death) is central to a number of physiological cellular processes and is essential in the maintenance of homeostasis and
Dr Jon Goldhill
The past fortnight saw a number of eHealth developments. Patients and consumer groups were particularly well catered for with the launch of important new cancer, diabetes, back pain, STD, substance ab
The pharmaceutical industry has a wide range of roles for medics, from clinical pharmacology where the clinical care of study subjects is your responsibility, to the position of medical adviser, which
Biopharmaceutical companies face numerous challenges to boost their output of new chemical entities and to strengthen their product pipelines. In order to remain profitable and competitive, they have
Non-compliance is the failure of patients to take medicines in their prescribed manner. Patient non-compliance is a serious healthcare issue, with studies showing that it can range from 20% to 80% dep
Four major brands, TAP’s Lupron, AstraZeneca’s Zoladex, Nolvadex and Casodex, account for 49% of the total value of the anti-hormonals market at present. The loss of patent protection for these compou
Over the past fortnight the Internet has benefited from Healthcare initiatives with a number of online health information tools being launched in particular. Schering-Plough led the way on this front but the leading pharmaceuticals were not all so happy. GlaxoSmithKline, for example, recently received criticism over its threat to stop supplying drugs to Canadian online pharmacies. These stories and others are covered in detail in this week’s eHealth News Roundup.
Lung cancer is one of the most prevalent forms of cancer to afflict both men and women, accounting for nearly 15% of all cancer cases. The size of the lung cancer market - estimated at $1.6bn in 2002
The current edition of TherapeuticAdvances features data on the targeting of ion channels and TNF-alpha for treatment of inflammation; stem cell approaches to cardiovascular angiogenesis; improved pro
Dr Jon Goldhill
Drug development is an expensive and risk-intensive process. Even if a company manages to get its products to market, success is not guaranteed as there is the threat of competitors to contend with.
Dr Faiz Kermani
In 2001, diabetes drugs represented six of the leading 100 pharmaceutical brands in terms of global sales, combining for $8.2 billion in sales. Sales were led by Bristol-Myers Squibb's Glucophage fran
The current edition of TherapeuticAdvances features data on anti-migraine drugs; emerging approaches to the blockade of transcription, angiogenesis and metastasis; and two therapeutic strategies for t
Dr Jon Goldhill
During the last year bioterrorism has attracted a high level of media and clinical attention. However, this publicity does not necessarily reflect a potential opportunity for easy market entry or high
The number of people with chronic heart failure in the western world is increasing so rapidly that, according to Datamonitor's EpiVision forecasts, by 2015 there will be 1.5 million sufferers in the UK alone. Although this is small in comparison to the 8.2 million already suffering from the condition in the US, the problem is great enough to represent a real danger for the already beleaguered NHS.
As the medical device field becomes more advanced the need for clinical trials will grow. With less experience of global clinical trials than those in the pharmaceutical sector, medical device compani
Dr Faiz Kermani and Jeff Kingston
The scientific community seemed to move into overdrive with the publication of the human genome, and the popular media responded this with reports of rapid advances to come in the field of human medic
According to new research pharmaceutical companies are investing more than ever to promote their drugs. Growth in promotional investment is thought to be increasing at a faster rate than growth in ethical sales. With this trend unlikely to continue because of economic constraint can the drug companies increase the impact of their marketing or do they face the prospect of slashing expenditure?
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her